This article based on the Oct 3, 2024 Insights FAWG Forum explores the potential for artificial intelligence (AI) to transform Medical Affairs, focusing on medical insights.
Regulatory bodies such as the Food and Drug Administration (FDA) and European Medicines Agency (EMA) are increasingly recognising the value of supplementing clinical trial data with real-world evidence to improve understanding of drug performance in the healthcare setting.
Consequently, Pharma companies are increasingly including real-world studies in their evidence to:
• Understand the opportunities and best practices for involving patient partners in the generation of real-world evidence
• Explore, using case studies, the value of patient engagement in the design, delivery, analysis and communication of real-world studies
• Highlight the importance of Medical Affairs and Health Economics and Outcomes Research (HEOR) professionals in partnering with colleagues from different functions in Pharma to ensure patients are effectively engaged throughout the product lifecycle
• Discuss barriers and propose solutions to optimal patient engagement in real-world studies
Experts from Pfizer and Veeva explore a recent Veeva Pulse Report showing that targeted scientific outreach is associated with 40% faster treatment adoption.
In this podcast, experts explore the many challenges associated with the operationalization of global Integrated Evidence Generation Planning (IEGP) at local levels.Â
This webinar, hosted by the MAPS APAC Chapter, aims to provide a comprehensive and practical overview of how Artificial Intelligence (AI) can be integrated into various functions of Medical Affairs. Attendees will gain insights into the application of AI in medical strategy, note-taking during advisory boards, setting agendas, and enhancing scientific communication. By the end of the session, participants will have a clear understanding of the tools and techniques available, and how to implement them effectively to improve efficiency and outcomes in their roles.
What makes a publication interesting or impactful? Is it number of citations? Sentiment among important stakeholders? Relevance to the largest patient population? Popular news attention? The answer depends on your strategy. Here we speak with experts from Altmetric about 10 publications that are impactful for different reasons.
Take advantage of alternative impact metrics that better reflect the multidimensional nature of today’s research dissemination and consumption.
In this webinar, we will share new data showing that while medical affairs is increasing in importance, it is still struggling to reach a consensus around medical impact metrics. However, measuring medical impact is no longer a choice; it’s a necessity for medical to communicate its value as a business function and better demonstrate its contributions to successful patient outcomes.
The Medical Affairs Professional Society (MAPS) is pleased to share our 2024 Digital, Advanced Analytics and Artificial Intelligence (AI) in Medical Affairs report. This report is based on findings from 32 leading organizations representing the Pharmaceutical, Biotech, and Medical and Diagnostic Device sectors, and reflects broad leadership thinking about the current and future states of Medical Affairs (MA) AI capability and challenges.
Survey design and analysis: Boston Consulting Group led the preparation, execution and analyses of the GenAI survey and moderated the Ambassador GenAI and Advanced Analytics workshop during the MAPS conference on March 24th, 2024.
Survey respondents: 34 representatives from 32 companies responded to our survey.
Participating companies: Thank you to participants from 3M, Abbott, AbbVie, Amgen, Astellas, AstraZeneca, Baxter, Bayer, bioMérieux, BioNTech, BMS, Eisai, Lilly, Gilead, Ipsen, Jazz Pharmaceuticals, Kyowa Kirin, Lundbeck, Mallinckrodt, Merck & Co, Mundipharma, Novartis, Otsuka, Regeneron, Sanofi, Sumitomo Pharma, Takeda, Teva, UCB, Varian, Vertex, and Viatris for your valuable feedback and insights.
The opinions expressed here are those of members of the MAPS Ambassador Alliance and do not necessarily represent the perspectives of their respective companies.
Experts from Lumanity discuss cross-functional alignment of Integrated Evidence Generation Planning (IEGP) from perspectives of strategy, clinical/regulatory, commercial and patient engagement.